CYRX

MKT CAP:$527M

Cryoport, Inc.

Market Cap

$527M

Industrials·Integrated Freight & Logistics·🇺🇸 United States·NASDAQ

Industrials·Integrated·🇺🇸·NASDAQ

Stock Price

$10.35+$0.79 (+8.26%)

Apr 17, 2026

Company Details

Cryoport, Inc., a life sciences services company, provides temperature-controlled logistics solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoportal, a cloud-based logistics management ...

CEO

Jerrell W. Shelton

IPO Date

Aug 22, 2005

Website

www.cryoport.com

Key Metrics TTM

Revenue

$197M

-5.2% YoY

Net Income

-$108M

EPS (Diluted)

-$2.34

Free Cash Flow

-$34M

Revenue / Share

$3.94

Gross Margin

45.2%

Operating Margin

-59.8%

Net Margin

-54.8%

FCF Margin

-17.5%

P/S

2.7x

P/E

—

Earnings Reports

Q2 2025

May 6, 2026

PENDING

FY 2025

Mar 5, 2026

$176MEPS $1.40

Q1 2025

May 8, 2025

$41M+10.1%EPS -$0.28

Q4 2024

Mar 7, 2025

$60M+4.0%EPS -$0.42

Q3 2024

Nov 7, 2024

$57M+0.9%EPS -$0.02

Revenue & Profitability

Quarter	Revenue	Gross Profit	Operating Income
Q2 21	$56M	$25M	-$4M
Q3 21	$57M	$24M	-$5M
Q4 21	$56M	$23M	-$8M
Q1 22	$52M	$22M	-$8M
Q2 22	$64M	$29M	-$5M
Q3 22	$60M	$26M	-$8M
Q4 22	$60M	$26M	-$11M
Q1 23	$63M	$27M	-$10M
Q2 23	$57M	$25M	-$18M
Q3 23	$56M	$24M	-$17M
Q4 23	$57M	$23M	-$70M
Q1 24	$37M	$15M	-$18M
Q2 24	$40M	$18M	-$78M
Q3 24	$57M	$25M	-$16M
Q4 24	$60M	$27M	-$14M
Q1 25	$41M	$19M	-$9M

Valuation

Quarter	P/S	P/E
Q2 21	3.1x	—
Q3 21	2.5x	—
Q4 21	2.4x	—
Q1 22	2.4x	—
Q2 22	2.3x	—
Q3 22	2.3x	—
Q4 22	2.2x	—
Q1 23	2.1x	—
Q2 23	2.2x	—
Q3 23	2.2x	—
Q4 23	2.3x	—
Q1 24	2.5x	—
Q2 24	2.8x	—
Q3 24	2.8x	—
Q4 24	2.7x	—
Q1 25	2.7x	—

Operating Cash Flow

Quarter	Operating CF	Free CF
Q2 21	$3M	-$2M
Q3 21	$9M	-$324.0K
Q4 21	$3M	-$6M
Q1 22	$524.0K	-$4M
Q2 22	-$7M	-$12M
Q3 22	$982.0K	-$5M
Q4 22	$4M	-$5M
Q1 23	$3M	-$7M
Q2 23	-$4M	-$15M
Q3 23	-$2M	-$13M
Q4 23	$2M	-$10M
Q1 24	-$3M	-$8M
Q2 24	-$8M	-$14M
Q3 24	$447.0K	-$1M
Q4 24	-$5M	-$11M
Q1 25	-$4M	-$8M

Capital Expenditures

Quarter	CapEx
Q2 21	$4M
Q3 21	$9M
Q4 21	$9M
Q1 22	$5M
Q2 22	$5M
Q3 22	$6M
Q4 22	$8M
Q1 23	$10M
Q2 23	$11M
Q3 23	$11M
Q4 23	$12M
Q1 24	$5M
Q2 24	$6M
Q3 24	$1M
Q4 24	$6M
Q1 25	$4M

CapEx

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q2 21	+498.5%	+293.4%
Q3 21	+407.5%	+179.7%
Q4 21	+16.7%	+11.3%
Q1 22	-1.8%	+10.5%
Q2 22	+14.2%	+15.8%
Q3 22	+6.7%	+11.4%
Q4 22	+6.9%	+10.2%
Q1 23	+20.1%	+21.2%
Q2 23	-11.1%	+8.6%
Q3 23	-7.1%	+7.0%
Q4 23	-5.1%	+78.1%
Q1 24	-40.6%	-24.8%
Q2 24	-30.4%	+56.2%
Q3 24	+0.9%	+0.0%
Q4 24	+4.0%	-42.2%
Q1 25	+10.1%	-7.8%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q2 21	$4M	7.2%
Q3 21	$4M	7.3%
Q4 21	$4M	7.4%
Q1 22	$4M	7.9%
Q2 22	$5M	8.2%
Q3 22	$5M	8.9%
Q4 22	$5M	8.8%
Q1 23	$5M	8.3%
Q2 23	$6M	10.2%
Q3 23	$6M	10.6%
Q4 23	$6M	10.2%
Q1 24	$5M	14.6%
Q2 24	$5M	12.6%
Q3 24	$5M	8.5%
Q4 24	$4M	7.4%
Q1 25	$3M	7.5%

OpEx Breakdown

Quarter	R&D	SG&A
Q2 21	$4M	$25M
Q3 21	$4M	$24M
Q4 21	$4M	$28M
Q1 22	$4M	$27M
Q2 22	$4M	$31M
Q3 22	$4M	$30M
Q4 22	$5M	$33M
Q1 23	$4M	$33M
Q2 23	$4M	$39M
Q3 23	$5M	$36M
Q4 23	$5M	$39M
Q1 24	$5M	$28M
Q2 24	$5M	$27M
Q3 24	$4M	$38M
Q4 24	$4M	$37M
Q1 25	$4M	$24M

Revenue Segments

Quarter	Product	Service	Animal Health	Biopharmaceutical	Reproductive Medicine
Q2 21	$27M	$30M	—	—	—
Q3 21	$26M	$31M	—	—	—
Q4 21	$25M	$32M	—	—	—
Q1 22	$19M	$33M	—	—	—
Q2 22	$30M	$35M	—	—	—
Q3 22	$27M	$33M	—	—	—
Q4 22	$27M	$33M	—	—	—
Q1 23	—	—	$9M	$51M	$3M
Q2 23	—	—	$8M	$47M	$3M
Q3 23	—	—	$7M	$47M	$2M
Q3 24	$17M	$39M	—	—	—
Q1 25	$18M	$23M	—	—	—

Revenue by Geography

Quarter	Americas	Asia Pacific	E M E A	Asia Pacific (APAC)	Europe, the Middle East and Africa (EMEA)	Emea
Q2 21	$29M	$12M	$15M	—	—	—
Q3 21	$30M	—	—	$12M	$14M	—
Q4 21	$33M	—	—	$8M	$16M	—
Q1 22	$28M	—	—	$8M	$16M	—
Q2 22	$35M	—	—	$12M	$17M	—
Q3 22	$34M	—	—	$10M	$16M	—
Q4 22	$31M	—	—	$36M	-$7M	—
Q1 23	$34M	—	—	$11M	$18M	—
Q2 23	$31M	—	—	$11M	$15M	—
Q3 23	$32M	—	—	$10M	$14M	—
Q3 24	$31M	$11M	—	—	—	$14M
Q1 25	$32M	$3M	—	—	—	$6M

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 22	$134M	$465M	$600M
Q2 22	$37M	$514M	$551M
Q3 22	$31M	$499M	$530M
Q4 22	$37M	$487M	$523M
Q1 23	$39M	$484M	$523M
Q2 23	$67M	$437M	$505M
Q3 23	$59M	$406M	$466M
Q4 23	$46M	$410M	$457M
Q1 24	$50M	$399M	$449M
Q2 24	$46M	$381M	$427M
Q3 24	$45M	$228M	$273M
Q4 24	$45M	$216M	$262M
Q1 25	$36M	$208M	$244M
Q2 25	$36M	$208M	$244M
Q3 25	$256M	$166M	$421M
Q4 25	$250M	$161M	$411M

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change	YoY Change
Q2 21	46M	+4.5%	+19.5%
Q3 21	46M	+0.8%	+17.9%
Q4 21	48M	+4.1%	+17.4%
Q1 22	50M	+3.4%	+13.4%
Q2 22	49M	-1.7%	+6.6%
Q3 22	49M	-0.6%	+5.2%
Q4 22	49M	-0.0%	+1.0%
Q1 23	48M	-0.3%	-2.6%
Q2 23	49M	+0.7%	-0.2%
Q3 23	49M	+0.4%	+0.8%
Q4 23	49M	+0.1%	+0.9%
Q1 24	49M	+0.1%	+1.4%
Q2 24	49M	+0.7%	+1.3%
Q3 24	49M	+0.1%	+1.1%
Q4 24	50M	+0.4%	+1.3%
Q1 25	50M	+0.7%	+1.9%

Shares Outstanding

Revenue Per Employee

Period	Revenue/Employee	Employees
Q2 21	$89.9K	625
Q3 21	$90.7K	625
Q4 21	$66.6K	847
Q1 22	$61.7K	847
Q2 22	$75.7K	847
Q3 22	$71.4K	847
Q4 22	$58.9K	1K
Q1 23	$61.3K	1K
Q2 23	$55.7K	1K
Q3 23	$54.8K	1K
Q4 23	$48.9K	1K
Q1 24	$31.9K	1K
Q2 24	$33.9K	1K
Q3 24	$48.4K	1K
Q4 24	$50.2K	1K
Q1 25	$34.6K	1K

Revenue / Employee